Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Hemagen Diagnostics stock

HMGN
US4235011057
885724

Price

0.00
Today +/-
+0
Today %
+0 %
P

Hemagen Diagnostics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Hemagen Diagnostics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Hemagen Diagnostics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Hemagen Diagnostics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Hemagen Diagnostics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Hemagen Diagnostics Stock Price History

DateHemagen Diagnostics Price
9/25/20240.00 undefined
9/23/20240.00 undefined
9/17/20240.00 undefined

Hemagen Diagnostics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hemagen Diagnostics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hemagen Diagnostics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hemagen Diagnostics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hemagen Diagnostics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hemagen Diagnostics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hemagen Diagnostics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hemagen Diagnostics’s growth potential.

Hemagen Diagnostics Revenue, EBIT and net profit per share

DateHemagen Diagnostics RevenueHemagen Diagnostics EBITHemagen Diagnostics Net Income
20124.04 M undefined-437,920 undefined-907,320 undefined
20115.14 M undefined-472,710 undefined-880,480 undefined
20105.22 M undefined235,950 undefined-156,310 undefined
20095.42 M undefined-348,000 undefined-807,000 undefined
20086.38 M undefined118,000 undefined428,000 undefined
20074.49 M undefined-159,000 undefined-850,000 undefined
20064.78 M undefined-170,000 undefined310,000 undefined
20057.59 M undefined-730,000 undefined-1.34 M undefined
20047.47 M undefined-510,000 undefined-3.6 M undefined
20038.47 M undefined250,000 undefined-1.27 M undefined
20029.5 M undefined-670,000 undefined-1.76 M undefined
200110.97 M undefined-260,000 undefined-2.2 M undefined
200011 M undefined-3.37 M undefined-5.13 M undefined
199914.59 M undefined-2.73 M undefined-5.16 M undefined
199812.33 M undefined100,000 undefined10,000 undefined
199712.99 M undefined510,000 undefined410,000 undefined
199610.22 M undefined-50,000 undefined-460,000 undefined
19953.96 M undefined-850,000 undefined-990,000 undefined
19942.36 M undefined-1.13 M undefined-1.11 M undefined
19931.81 M undefined-630,000 undefined-1.25 M undefined

Hemagen Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012
000112310121214111098774465554
-----100.0050.00233.3320.00-16.67-21.43-9.09-10.00-11.11-12.50--42.86-50.00-16.67---20.00
----100.0050.0033.3330.0041.6741.6721.439.0930.0022.2225.0028.5714.2925.0025.0033.3340.0040.0020.0025.00
000011135531322211122211
00000-10000-2-3000000000000
------50.00-----14.29-27.27------------
0000-1-10000-5-5-2-1-1-3-10000000
-------------60.00-50.00-200.00-66.67-------
2.142.142.142.142.723.153.165.677.817.917.789.79.7510.0410.110.1115.215.315.2315.2315.2315.4515.4815.5
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Hemagen Diagnostics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hemagen Diagnostics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012
                                           
0.060.982.991.422.142.121.030.410.291.460.670.460.720.540.270.150.010.10.160.150.210.07
0.090.240.290.480.951.672.293.31.881.71.31.181.140.960.96110.870.630.670.580.59
00000000000000000210210210350
0.010.030.390.351.093.183.956.215.674.193.773.373.253.342.762.762.552.041.71.391.461.36
3022090120200270220270290180110180170150280280255304120352.53159.4977.89
0.191.473.762.374.387.247.4910.198.137.535.855.195.284.994.274.193.823.522.822.772.452.09
0.090.091.072.432.542.932.554.373.773.082.231.6310.471.020.160.220.70.60.530.390.28
103000000000000000000000
000000000000000004552453500
0000000000000000000000
000001.581.471.360.250.200.150.150.1500000000
010050504006040400120300505010404095985440.2552.6665.69
0.10.221.122.482.944.574.065.774.023.42.531.831.20.631.060.20.321.250.90.60.440.35
0.291.694.884.857.3211.8111.5515.9612.1510.938.387.026.485.625.334.394.134.773.723.372.892.44
                                           
202030303080808080100100100100150150150153153153155.65155.85156
0.010.544.964.965.1613.1313.3313.4413.4419.2320.6920.9320.9522.8322.8322.8422.8422.8722.9222.9623.0423.13
1030-1,220-2,330-3,320-3,780-3,380-3,370-8,530-13,660-15,850-17,610-18,880-22,480-23,820-23,500-24,353-23,926-24,734-24,890.44-25,770.92-26,678.23
0-10-10-10-10-10-10-10-100-80-130-160-150-100-100-49-100-3117.91-20.59-78.55
0000000000000000000000
0.040.583.762.651.869.4210.0210.144.985.674.863.292.010.35-0.94-0.61-1.41-1.01-1.69-1.76-2.6-3.47
0.070.190.391.060.560.650.380.61.040.860.530.610.620.870.910.530.850.740.560.310.420.37
00000.220.780.410.491.081.971.130.820.770.710.570.70.480.390.410.430.40.58
202000200015080020013012060504030181035227.3437.2320.98
0.080.86000.3800.23.53.17000001.0500.364.510.430.40.670.98
0.020.020.190.330.670.40.3501.161.050.140.1600.020.030000000
0.191.090.581.391.851.831.344.747.254.081.931.711.451.652.61.261.715.741.451.171.531.95
0.010.020.540.823.590.560.191.0701.271.692.123.113.713.763.843.920.124.054.054.054.05
0000000000000000000000
40000000000000000000000
0.050.020.540.823.590.560.191.0701.271.692.123.113.713.763.843.920.124.054.054.054.05
0.241.111.122.215.442.391.535.817.255.353.623.834.565.366.365.15.635.865.55.225.586
0.281.694.884.867.311.8111.5515.9512.2311.028.487.126.575.715.424.494.224.863.813.462.982.53
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hemagen Diagnostics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hemagen Diagnostics's financial health and stability.

Assets

Hemagen Diagnostics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hemagen Diagnostics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hemagen Diagnostics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hemagen Diagnostics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (k)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012
000-1-10000-5-5-2-1-1-3-10000000
0000000001,0001,000000000000000
00000000000000000000000
0000000-1012000000000000
00000000020101200000000
00000000000000000000000
00000000000000000000000
0000000000-1000000000000
00000000000000000000000
000-2,0000-1,000-5,0000-3,00000000001,000000000
000-2,00000-5,0000-2,00000000001,000000000
00000000000000000000000
001-103-2020-200001-1000000
00040060005000000000000
0003024020300001-1000000
-----------------------
00000000000000000000000
000001,00000001,000000000000000
0.07-0.020.03-1.08-1.31-0.930.3-0.490.05-0.53-2.30.06-0.050.45-0.21-1.32-0.76-0.53-0.1-0.1-0.26-0.39-0.45
00000000000000000000000

Hemagen Diagnostics stock margins

The Hemagen Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hemagen Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hemagen Diagnostics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hemagen Diagnostics's sales revenue. A higher gross margin percentage indicates that the Hemagen Diagnostics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hemagen Diagnostics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hemagen Diagnostics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hemagen Diagnostics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hemagen Diagnostics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hemagen Diagnostics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hemagen Diagnostics Margin History

Hemagen Diagnostics Gross marginHemagen Diagnostics Profit marginHemagen Diagnostics EBIT marginHemagen Diagnostics Profit margin
201239.92 %-10.83 %-22.45 %
201138.14 %-9.19 %-17.13 %
201045.14 %4.52 %-2.99 %
200938.25 %-6.42 %-14.89 %
200843.48 %1.85 %6.71 %
200741.92 %-3.54 %-18.94 %
200639.75 %-3.56 %6.49 %
200525.16 %-9.62 %-17.65 %
200428.78 %-6.83 %-48.19 %
200335.3 %2.95 %-14.99 %
200230.95 %-7.05 %-18.53 %
200131.08 %-2.37 %-20.05 %
200012.55 %-30.64 %-46.64 %
199921.8 %-18.71 %-35.37 %
199840.79 %0.81 %0.08 %
199741.49 %3.93 %3.16 %
199638.85 %-0.49 %-4.5 %
199544.7 %-21.46 %-25 %
199450 %-47.88 %-47.03 %
199358.56 %-34.81 %-69.06 %

Hemagen Diagnostics Stock Sales Revenue, EBIT, Earnings per Share

The Hemagen Diagnostics earnings per share therefore indicates how much revenue Hemagen Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hemagen Diagnostics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hemagen Diagnostics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hemagen Diagnostics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hemagen Diagnostics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hemagen Diagnostics Revenue, EBIT and net profit per share

DateHemagen Diagnostics Sales per ShareHemagen Diagnostics EBIT per shareHemagen Diagnostics Earnings per Share
20120.26 undefined-0.03 undefined-0.06 undefined
20110.33 undefined-0.03 undefined-0.06 undefined
20100.34 undefined0.02 undefined-0.01 undefined
20090.36 undefined-0.02 undefined-0.05 undefined
20080.42 undefined0.01 undefined0.03 undefined
20070.29 undefined-0.01 undefined-0.06 undefined
20060.31 undefined-0.01 undefined0.02 undefined
20050.5 undefined-0.05 undefined-0.09 undefined
20040.74 undefined-0.05 undefined-0.36 undefined
20030.84 undefined0.02 undefined-0.13 undefined
20020.95 undefined-0.07 undefined-0.18 undefined
20011.13 undefined-0.03 undefined-0.23 undefined
20001.13 undefined-0.35 undefined-0.53 undefined
19991.88 undefined-0.35 undefined-0.66 undefined
19981.56 undefined0.01 undefined0 undefined
19971.66 undefined0.07 undefined0.05 undefined
19961.8 undefined-0.01 undefined-0.08 undefined
19951.25 undefined-0.27 undefined-0.31 undefined
19940.75 undefined-0.36 undefined-0.35 undefined
19930.67 undefined-0.23 undefined-0.46 undefined

Hemagen Diagnostics business model

Hemagen Diagnostics Inc is a company that was founded in 1985. The company is based in Columbia, Maryland and is involved in medical diagnostics. Hemagen specializes in the development of diagnostic test kits that help doctors and laboratories identify and treat medical conditions and diseases. Hemagen Diagnostics offers a wide range of products in the field of diagnostics and medical research. Their offerings include diagnostic test kits for autoimmune diseases, infectious diseases, enzymes, proteins, and hormones. These test kits are used by medical professionals and laboratories worldwide. The business model of Hemagen Diagnostics is focused on providing its customers with the best diagnostic test kits on the market. The company has developed a wide range of products and services for a broad spectrum of medical conditions and diseases. Hemagen Diagnostics' core business is the production of test kits for laboratories and medical professionals. One of Hemagen Diagnostics' main areas of focus is disease diagnosis. The company has developed an extensive range of diagnostic test kits that facilitate the diagnosis of various diseases. This includes test kits for diseases such as HIV, hepatitis, and infectious diseases like chlamydia and gonorrhea. Hemagen also produces test kits for autoimmune diseases such as rheumatoid arthritis and lupus. Another focus of Hemagen Diagnostics is the development of test kits for medical research. The company has created a wide selection of test kits that can be used for research projects. This includes test kits for hormones, proteins, and enzymes. These test kits are suitable for a range of research applications such as biomarker identification and the study of metabolic processes. Over the years, Hemagen Diagnostics has expanded and improved its range of products and services. The company has continuously expanded and enhanced its division for the development of diagnostic test kits. It has also established a number of partnerships with other companies and institutes in the field of medical diagnostics. In conclusion, Hemagen Diagnostics Inc is a leading provider of diagnostic test kits for medical diagnostics and research. The company specializes in the development of state-of-the-art tests for disease diagnosis and the investigation of biomolecular processes. Hemagen Diagnostics has a strong reputation within the medical community and is continuously working on improving and expanding its product range. Hemagen Diagnostics is one of the most popular companies on Eulerpool.com.

Hemagen Diagnostics SWOT Analysis

Strengths

Hemagen Diagnostics Inc has several strengths that contribute to its success in the market. One of the key strengths is its innovative and advanced diagnostic technology, which allows for accurate and efficient testing procedures. The company also boasts a highly skilled and experienced team of scientists and researchers, enabling them to develop cutting-edge solutions for diagnostic challenges. Additionally, Hemagen Diagnostics Inc has built a strong reputation for quality and reliability among its customers.

Weaknesses

Despite its strengths, Hemagen Diagnostics Inc faces certain weaknesses that may hinder its growth potential. One weakness is the company's limited global presence, primarily focusing on a specific region or market segment. This limits their exposure to potential international growth opportunities. Another weakness is the company's dependence on external suppliers for certain critical components, which may pose risks in terms of quality control and supply chain disruptions.

Opportunities

Hemagen Diagnostics Inc operates in a rapidly evolving healthcare industry, presenting several opportunities for growth and expansion. The increasing demand for accurate and efficient diagnostic tests, driven by factors such as an aging population and rising healthcare awareness, provides a significant market opportunity. Furthermore, advancements in technology offer the chance for Hemagen Diagnostics Inc to develop new products and services that cater to emerging diagnostic needs.

Threats

Several external factors pose threats to Hemagen Diagnostics Inc's business operations. One of these threats is intensifying competition from both established players and emerging startups in the diagnostic industry. This heightens the need for continuous innovation and differentiation to maintain a competitive edge. Economic fluctuations and healthcare regulatory changes also pose threats, as they can impact the purchasing power of customers and affect the demand for diagnostic products and services.

Hemagen Diagnostics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Hemagen Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio

Hemagen Diagnostics shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hemagen Diagnostics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hemagen Diagnostics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hemagen Diagnostics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hemagen Diagnostics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Hemagen Diagnostics.

Hemagen Diagnostics shareholders

%
Name
Stocks
Change
Date
0 % Formidable Asset Management, LLC0-51,50012/31/2023
1

Hemagen Diagnostics Executives and Management Board

William Hales50
Hemagen Diagnostics Chairman of the Board, President, Chief Executive Officer (since 1999)
Compensation 192,348
Catherine Davidson47
Hemagen Diagnostics Principal Accounting Officer, Controller
Compensation 110,797
M. Robert Campbell43
Hemagen Diagnostics Chief Financial Officer
Dr. Alan Cohen86
Hemagen Diagnostics Independent Director
Edward Lutz66
Hemagen Diagnostics Independent Director
1

Most common questions regarding Hemagen Diagnostics

What values and corporate philosophy does Hemagen Diagnostics represent?

Hemagen Diagnostics Inc represents a commitment to delivering reliable diagnostic solutions and improving patient care. The company values innovation and strives to develop cutting-edge technologies in the field of diagnostics. With a focus on accuracy and efficiency, Hemagen Diagnostics Inc aims to provide healthcare professionals with accurate and timely test results. The company's corporate philosophy revolves around integrity, customer satisfaction, and collaboration with healthcare providers. Hemagen Diagnostics Inc is dedicated to making a positive impact in the medical industry by offering high-quality diagnostic products and fulfilling the evolving needs of the market.

In which countries and regions is Hemagen Diagnostics primarily present?

Hemagen Diagnostics Inc is primarily present in the United States.

What significant milestones has the company Hemagen Diagnostics achieved?

Hemagen Diagnostics Inc has achieved several significant milestones since its establishment. The company has made notable strides in the field of diagnostics, particularly in the development of advanced laboratory tests and technologies. Hemagen Diagnostics Inc has successfully introduced innovative solutions that enhance the accuracy and efficiency of diagnostic processes. Through their commitment to research and development, the company has also expanded its product portfolio, catering to various medical needs. Continuously striving for excellence, Hemagen Diagnostics Inc has gained recognition for its contributions in the healthcare industry and remains dedicated to providing reliable diagnostic solutions to healthcare professionals and patients worldwide.

What is the history and background of the company Hemagen Diagnostics?

Hemagen Diagnostics Inc is a renowned company in the field of medical diagnostics. Founded in 1985, Hemagen has been dedicated to providing innovative diagnostic solutions to the healthcare industry. With its headquarters in Columbia, Maryland, the company has gained a strong presence in the market over the years. Hemagen specializes in developing and manufacturing cutting-edge diagnostic tests for various medical conditions, including infectious diseases, autoimmune disorders, and cancer. Their commitment to delivering accurate and reliable results has garnered them a loyal customer base. Hemagen Diagnostics Inc continues to strive for excellence in medical diagnostics, positioning itself as a trusted name in the industry.

Who are the main competitors of Hemagen Diagnostics in the market?

Some of the main competitors of Hemagen Diagnostics Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad Laboratories, and Siemens Healthineers.

In which industries is Hemagen Diagnostics primarily active?

Hemagen Diagnostics Inc primarily operates in the healthcare industry.

What is the business model of Hemagen Diagnostics?

The business model of Hemagen Diagnostics Inc. focuses on the development, manufacturing, and distribution of innovative diagnostic products and services. Hemagen Diagnostics Inc. specializes in providing cutting-edge medical technologies for the healthcare industry. By leveraging their expertise in diagnostics, Hemagen Diagnostics Inc. aims to improve patient outcomes by providing accurate and timely diagnostic solutions. Through their wide range of products, Hemagen Diagnostics Inc. caters to various healthcare settings, including hospitals, laboratories, and physicians' offices. With a commitment to research and development, Hemagen Diagnostics Inc. continually strives to introduce new and advanced diagnostic solutions to meet the evolving needs of the medical community.

What is the P/E ratio of Hemagen Diagnostics 2024?

The P/E ratio cannot be calculated for Hemagen Diagnostics at the moment.

What is the P/S ratio of Hemagen Diagnostics 2024?

The P/S cannot be calculated for Hemagen Diagnostics currently.

What is the AlleAktien quality score of Hemagen Diagnostics?

The AlleAktien quality score for Hemagen Diagnostics is 3/10.

What is the revenue of Hemagen Diagnostics 2024?

The revenue cannot currently be calculated for Hemagen Diagnostics.

How high is the profit of Hemagen Diagnostics 2024?

The profit cannot currently be calculated for Hemagen Diagnostics.

What is the business model of Hemagen Diagnostics

Hemagen Diagnostics is an In-Vitro Diagnostics manufacturer based in New Jersey since 1985. The company offers a wide range of tests for diseases and blood disorders. Thanks to its extensive experience and innovative diagnostic technologies, Hemagen Diagnostics is a leader in the world of IVD medicine. Hemagen Diagnostics operates globally and has customers in over 50 countries. The company conducts its business in three main divisions: Specialty Laboratories, Medical Technology, and Global Markets. The Specialty Laboratories are responsible for manufacturing blood products and diagnostic reagents for hospitals and clinics. The Medical Technology division is in charge of commercializing and distributing products for rapid diagnostics of blood disorders and pregnancy tests. Finally, the Global Markets division is responsible for selling products in countries outside the USA. Hemagen Diagnostics produces a wide range of products for various applications, including blood tests for anemia, hemoglobinopathies, and severe infectious diseases. The products range from simple rapid tests to complex blood screenings for hospitals and medical laboratories. A core product of Hemagen Diagnostics is the supplied ELISA test for identification and quantification of human proteins. The company also offers an innovative laboratory system for automated testing, which significantly improves time management for medical professionals and laboratories. Another important product line of Hemagen Diagnostics includes tests for chronic lymphocytic leukemia (CLL) and malignant lymphomas, which were developed in collaboration with Accumen Diagnostics. These tests use proprietary technologies to enhance the diagnosis and treatment processes for these challenging diseases. Hemagen Diagnostics is committed to providing the latest technologies and methods for IVD medicine. The company is constantly seeking new opportunities for innovation and efficiency optimization to succeed in a rapidly changing world of clinical diagnostics. Overall, Hemagen Diagnostics' business model is designed for long-term success in a challenging and expanding industry. The three divisions of the company enable a wide range of products and offer a variety of opportunities for customers and relationships worldwide.

What is the Hemagen Diagnostics dividend?

Hemagen Diagnostics pays a dividend of 0 USD distributed over payouts per year.

How often does Hemagen Diagnostics pay dividends?

The dividend cannot currently be calculated for Hemagen Diagnostics or the company does not pay out a dividend.

What is the Hemagen Diagnostics ISIN?

The ISIN of Hemagen Diagnostics is US4235011057.

What is the Hemagen Diagnostics WKN?

The WKN of Hemagen Diagnostics is 885724.

What is the Hemagen Diagnostics ticker?

The ticker of Hemagen Diagnostics is HMGN.

How much dividend does Hemagen Diagnostics pay?

Over the past 12 months, Hemagen Diagnostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hemagen Diagnostics is expected to pay a dividend of 0 USD.

What is the dividend yield of Hemagen Diagnostics?

The current dividend yield of Hemagen Diagnostics is .

When does Hemagen Diagnostics pay dividends?

Hemagen Diagnostics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hemagen Diagnostics?

Hemagen Diagnostics paid dividends every year for the past 0 years.

What is the dividend of Hemagen Diagnostics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hemagen Diagnostics located?

Hemagen Diagnostics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hemagen Diagnostics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hemagen Diagnostics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Hemagen Diagnostics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Hemagen Diagnostics in the year 2023?

In the year 2023, Hemagen Diagnostics distributed 0 USD as dividends.

In which currency does Hemagen Diagnostics pay out the dividend?

The dividends of Hemagen Diagnostics are distributed in USD.

All fundamentals about Hemagen Diagnostics

Our stock analysis for Hemagen Diagnostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hemagen Diagnostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.